| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WFDC2 |
| Uniprot No | Q14508 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-124aa |
| 氨基酸序列 | EKTGVCPELQADQNCTQECVSDSECADNLKCCSAGCATFCSLPNDKEGSC PQVNINFPQLGLCRDQCQVDSQCPGQMKCCRNGCGKVSCVTPNF |
| 预测分子量 | 11 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于WFDC2(HE4)重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**: *"Recombinant HE4 protein promotes proliferation of pancreatic cancer cells via the downregulation of S100A6"*
**作者**: Zhuang H, et al.
**摘要**: 研究通过表达并纯化重组HE4蛋白，发现其能通过抑制S100A6基因的表达，促进胰腺癌细胞增殖，揭示了HE4在肿瘤进展中的潜在机制。
2. **文献名称**: *"Development of a novel ELISA for human epididymis protein 4 (HE4) and its application in ovarian cancer diagnosis"*
**作者**: Moore RG, et al.
**摘要**: 该研究利用重组HE4蛋白作为抗原开发了高灵敏ELISA检测方法，证实HE4在卵巢癌早期诊断中的临床价值，并验证了其与CA125联合检测的优势。
3. **文献名称**: *"Structural and functional analysis of WFDC2/HE4 in cancer-associated pathways"*
**作者**: Bingle L, et al.
**摘要**: 通过重组表达WFDC2蛋白，解析其三维结构及与蛋白酶抑制功能相关的关键位点，探讨了其在肿瘤微环境中调节免疫反应的分子机制。
(注：以上文献信息为模拟示例，实际引用需查询PubMed或学术数据库获取具体文献。)
WFDC2 (WAP four-disulfide core domain protein 2), also known as HE4 (human epididymis protein 4), is a small secretory glycoprotein belonging to the WAP-type protease inhibitor family. It is characterized by a conserved structural motif containing eight cysteine residues that form four disulfide bonds, stabilizing its functional conformation. Initially identified in the epididymis, WFDC2 is expressed in multiple tissues, including reproductive organs, respiratory epithelia, and glandular tissues, suggesting roles in innate immunity and epithelial homeostasis.
Physiologically, WFDC2 is implicated in modulating proteolytic activity, particularly by inhibiting serine proteases involved in inflammatory responses and pathogen defense. Its expression is regulated by estrogen and other hormonal signals, linking it to reproductive biology. However, WFDC2 gained significant attention in clinical research due to its overexpression in certain cancers, notably ovarian and endometrial carcinomas. It has emerged as a valuable biomarker for ovarian cancer diagnosis, prognosis, and monitoring, often used in combination with CA125 to improve diagnostic accuracy.
Recombinant WFDC2 is produced using heterologous expression systems (e.g., E. coli, mammalian cells) to ensure proper folding and post-translational modifications. The recombinant protein retains biological activity, enabling studies on its molecular interactions, signaling pathways, and therapeutic potential. It serves as a critical reagent in developing immunoassays, functional studies exploring tumor progression mechanisms, and drug discovery platforms targeting WFDC2-associated pathways. Current research also investigates its role in chronic inflammatory diseases and fibrosis, expanding its biomedical relevance beyond oncology.
×
